<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcimmunol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Immunology - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcimmunol/</link>
        <description>The latest research articles published by BMC Immunology</description>
        <dc:date>2013-05-17T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/23" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/22" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/21" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/20" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/19" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/13" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/18" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/17" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/16" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/14/15" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/23">
        <title>Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia</title>
        <description>Background:
Hepatitis C virus (HCV) is an RNA virus which has been known to cause acute and chronic necro-inflammatory disease of the liver. It is the leading cause of end-stage liver disease and hepatocellular carcinoma. HIV is known to have a negative impact on the natural disease outcome and immune response of HCV infection, whereas the reverse remains unclear. We evaluated the impact of HCV co-infection on recovery of CD4+ and CD8+ T-cells and liver enzyme levels before and after initiation of highly active antiretroviral therapy (HAART) in HIV/HCV co-infected patients.
Methods:
A hospital-based, observational, prospective cohort study design was used for this study. Pre-antiretroviral treatment (Pre-ART) and under HAART HIV mono-infected and HCV/HIV co-infected individuals who are under regular follow-up were recruited for this study. 387 blood samples were collected from volunteer, known HIV positive Ethiopian patients and screened for HCV. Twenty five HCV/HIV co-infected patients were prospectively followed for four years. CD4+ and CD8+ T-cells and liver enzyme levels were determined annually for each of the participant.
Results:
The prevalence of HCV/HIV co-infection in this study was 6.5%. Both HCV/HIV co-infected and HIV mono-infected under HAART groups showed CD4+ recovery (343 Vs 426; P &lt; 0.004, OR = 4.97, 95% CI = 2.41 to 10.27) respectively; but, the recovery rate was higher in mono-infected (80 Vs 426) than co-infected group (148 Vs 343). The recovery and/or decline pattern of CD8+ T-cells was the same with that of CD4+. In 75% of co-infected groups, the mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were above the upper limit of normal reference range. Analyses restricted to individuals who initiated HAART and pre-ART showed similar results.
Conclusion:
We found that CD4+ T-cell recovery was negatively affected by the presence of ongoing HCV replication in under HAART co-infected individuals and fast decline of CD4+ T-cells in pre-ART patients. It was also associated with increased ALT and AST enzyme levels in both HAART initiated and treatment naive co-infected patients.</description>
        <link>http://www.biomedcentral.com/1471-2172/14/23</link>
                <dc:creator>Solomon Taye</dc:creator>
                <dc:creator>Mekuria Lakew</dc:creator>
                <dc:source>BMC Immunology 2013, null:23</dc:source>
        <dc:date>2013-05-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-23</dc:identifier>
                                <prism:require>/content/figures/1471-2172-14-23-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>23</prism:startingPage>
        <prism:publicationDate>2013-05-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/22">
        <title>Expression of Toll-like Receptors 2 and 9 in cells of dog jejunum and colon naturally infected with Leishmania infantum</title>
        <description>Background:
Infection with parasite protozoa is a long-term health issue in tropical and subtropical regions throughout the world. The Toll-like receptor (TLR) signaling pathway is one of the first-responding defense systems against Leishmania. The aim of this study was to investigate the expression of TLR2 and TLR9 in jejunum and colon and its correlation with CD11c, CD11b, and CD14 receptors used as markers for dendritic cells and macrophages.
Methods:
Twenty four dogs infected with Leishmania infantum were used in this study. Cytometry was carried out in lamina propria cells from jejunum and colon using markers for TLR2, TLR9, CD11b, CD11c and CD14.
Results:
Cellular inflammatory exudate was diffuse in the mucosa and submucosa, predominately comprising mononuclear cells: plasma cells, macrophages, and lymphocytes. Despite the parasite load, microscopy showed no erosion was evident in the epithelial mucosa layers. The colon harbored more parasites than the jejunum. Flow cytometry revealed higher frequency of TLR2+ and CD11c+ dendritic cells in the colon than in the jejunum. Conversely, TLR9-expressing cells were more frequent in jejunum. Moreover, frequency of macrophages (CD11b+ and CD14+) expressing simultaneity TLR9 were lower in the colon than in jejunum, while CD11c+ cells predominated in the colon. Despite of the negative ELISA serum results, IL-10 and TNF-alpha were higher in jejunum than colon of infected animals. However, IL-4 was higher in colon than jejunum of infected animals. A higher expression these cytokines were demonstrated in infected dogs compared to uninfected dogs.
Conclusions:
There was no correlation between clinical signs and pathological changes and immunological and parasitological findings in the gastrointestinal tract in canine visceral leishmaniasis. However, jejunum showed a lower parasite load with increased frequency and expression of CD11b, TLR9, CD14/CD11b/TLR9 receptors and IL-10 and TNF-alpha cytokines. Conversely, the colon showed a higher parasite load along with increased frequency and expression of TLR2, CD11c receptors, and IL-4 cytokine. Thus, Leishmania infantum is able to interfere in jejunum increased expression of TLR2, TLR9, CD11b, CD14, CD14/CD11b/TLR9 receptors, IL-10, and TNF-alpha; and in colon increased expression of CD11c, TLR2, TLR9, CD11b, CD14 e, CD14/CD11b/TLR9 receptors, IL-10, and TNF-alpha.</description>
        <link>http://www.biomedcentral.com/1471-2172/14/22</link>
                <dc:creator>Maria Figueiredo</dc:creator>
                <dc:creator>Izabela Amorim</dc:creator>
                <dc:creator>Aldair Pinto</dc:creator>
                <dc:creator>Vítor Barbosa</dc:creator>
                <dc:creator>Lucélia de Jesus Pinheiro</dc:creator>
                <dc:creator>Beatriz Deoti</dc:creator>
                <dc:creator>Ana Faria</dc:creator>
                <dc:creator>Wagner Tafuri</dc:creator>
                <dc:source>BMC Immunology 2013, null:22</dc:source>
        <dc:date>2013-05-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-22</dc:identifier>
                                <prism:require>/content/figures/1471-2172-14-22-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>22</prism:startingPage>
        <prism:publicationDate>2013-05-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/21">
        <title>The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese</title>
        <description>Genetic polymorphisms observed in various disease states associated with sensitivity or resistance to specific treatments have been a robust area of investigation for decades, with the potential to allow clinicians to make evidence-based decisions on the appropriate course of treatment. This study aimed to evaluate whether genetic polymorphisms of the signal transducer and activator of transcription 6 gene (STAT6) could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFN&#945;-RBV). We analyzed the associations between SVR to PEG-IFN&#945;-RBV therapy and 4 single nucleotide polymorphisms (SNPs) in STAT6. This study included Taiwanese Chinese patients infected with either HCV-1 (n&#8201;=&#8201;265) or HCV-2 (n&#8201;=&#8201;195) in the presence or absence of an SVR. Among the STAT6 SNPs examined, the dosage effect of the A allele and allele frequency in rs1059513 were inversely correlated with SVR in patients infected with HCV-1 (P&#8201;=&#8201;0.0179 and P&#8201;=&#8201;0.0235, respectively). This effect was not observed in patients infected with HCV-2. The GG, GGG, and GGGC STAT6 haplotypes comprising 2, 3, and 4 SNPs (rs1059513, rs703817, rs324015, and rs3024974) were found to be associated with SVR, and their presence may increase the probability of a successful treatment outcome in patients infected with HCV-1 (P&#8201;=&#8201;0.0273, 0.0352, and 0.0368, respectively). Moreover, a multivariate logistic regression model for predicting an SVR revealed that the presence of the GGGC haplotype carriers mutually affected the outcome of PEG-IFN&#945;-RBV treatment. The presence of STAT6 SNPs and the association with SVR demonstrated that STAT6 polymorphisms might influence the therapeutic outcomes of patients infected with HCV-1 under standard-of-care (SOC) treatment.</description>
        <link>http://www.biomedcentral.com/1471-2172/14/21</link>
                <dc:creator>Yun-Ping Lim</dc:creator>
                <dc:creator>Yu-An Hsu</dc:creator>
                <dc:creator>Kun-Hsi Tsai</dc:creator>
                <dc:creator>Fuu-Jen Tsai</dc:creator>
                <dc:creator>Cheng-Yuan Peng</dc:creator>
                <dc:creator>Wen-Ling Liao</dc:creator>
                <dc:creator>Dong-Zong Hung</dc:creator>
                <dc:creator>Ni Tien</dc:creator>
                <dc:creator>Chien-Yih Lin</dc:creator>
                <dc:creator>Lei Wan</dc:creator>
                <dc:source>BMC Immunology 2013, null:21</dc:source>
        <dc:date>2013-05-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-21</dc:identifier>
                                <prism:require>/content/figures/1471-2172-14-21-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2013-05-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/20">
        <title>Inhibitory effect of IL-17 on neural stem cell proliferation and neural cell differentiation</title>
        <description>Background:
IL-17, a Th17 cell-derived proinflammatory molecule, has been found to play an important role in the pathogenesis of autoimmune diseases, including multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). While IL-17 receptor (IL-17R) is expressed in many immune-related cells, microglia, and astrocytes, it is not known whether IL-17 exerts a direct effect on neural stem cells (NSCs) and oligodendrocytes, thus inducing inflammatory demyelination in the central nervous system.
Methods:
We first detected IL-17 receptor expression in NSCs with immunostaining and real time PCR. We then cultured NSCs with IL-17 and determined NSC proliferation by neurosphere formation capability and cell number count, differentiation by immunostaining neural specific markers, and apoptosis of NSCs by flow cytometry.
Results:
NSCs constitutively express IL-17R, and when the IL-17R signal pathway was activated by adding IL-17 to NSC culture medium, the number of NSCs was significantly reduced and their ability to form neurospheres was greatly diminished. IL-17 inhibited NSC proliferation, but did not induce cytotoxicity or apoptosis. IL-17 hampered the differentiation of NSCs into astrocytes and oligodendrocyte precursor cells (OPCs). The effects of IL-17 on NSCs can be partially blocked by p38 MAPK inhibitor.
Conclusions:
IL-17 blocks proliferation of NSCs, resulting in significantly reduced numbers of astrocytes and OPCs. Thus, in addition to its proinflammatory role in the immune system, IL-17 may also play a direct role in blocking remyelination and neural repair in the CNS.</description>
        <link>http://www.biomedcentral.com/1471-2172/14/20</link>
                <dc:creator>Zichen Li</dc:creator>
                <dc:creator>Ke Li</dc:creator>
                <dc:creator>Lin Zhu</dc:creator>
                <dc:creator>Quancheng Kan</dc:creator>
                <dc:creator>Yaping Yan</dc:creator>
                <dc:creator>Priyanka Kumar</dc:creator>
                <dc:creator>Hui Xu</dc:creator>
                <dc:creator>Abdolmohamad Rostami</dc:creator>
                <dc:creator>Guang-Xian Zhang</dc:creator>
                <dc:source>BMC Immunology 2013, null:20</dc:source>
        <dc:date>2013-04-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-20</dc:identifier>
                                <prism:require>/content/figures/1471-2172-14-20-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>20</prism:startingPage>
        <prism:publicationDate>2013-04-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/19">
        <title>The distribution of IgG subclass deposition on renal tissues from patients with anti-glomerular basement membrane disease</title>
        <description>Background:
Renal injury of anti-glomerular basement membrane (GBM) disease is defined by the linear deposition of IgG along GBM and rapidly progressive glomerulonephritis. To date, the distribution of anti-GBM IgG subclasses on renal tissue is still unclear. In the current study, we investigated the deposition of the four IgG subclasses using immunohistochemistry in the renal biopsy specimens from 46 patients with anti-GBM disease.
Results:
All four IgG subclasses can be detected within the GBM. Anti-GBM IgG3 was detected in all patients (100%), with 39 (84.8%) patients presenting with weak segmental staining and 7 (15.2%) patients with strong linear deposition. Anti-GBM IgG2 was detected in 22 (47.8%) patients, with 20 (90.9%) patients having weak segmental deposition and 2 (9.1%) patients presenting strong linear staining. Anti-GBM IgG1 and IgG4 were detected in 9 (19.6%) and 7 (15.2%) patients, respectively. IgG deposition along tubular basement membrane (TBM) was also detected in 31 (67.4%) patients. Among them, the IgG subclass distribution was similar to that of the deposition within the GBM: IgG1 6.5% (2/31), IgG2 45.2% (14/31), IgG3 100% (31/31) and IgG4 9.7% (3/31). We observed increased inflammatory cell infiltration into the interstitium in patients with increased anti-TBM IgG3 deposits (P=0.031).
Conclusions:
Anti-GBM IgG3 predominantly deposits along GBM and TBM on renal biopsy specimens from patients with anti-GBM disease, which may be involved in the development of renal injury of the disease.</description>
        <link>http://www.biomedcentral.com/1471-2172/14/19</link>
                <dc:creator>Zhen Qu</dc:creator>
                <dc:creator>Zhao Cui</dc:creator>
                <dc:creator>Gang Liu</dc:creator>
                <dc:creator>Ming-hui Zhao</dc:creator>
                <dc:source>BMC Immunology 2013, null:19</dc:source>
        <dc:date>2013-04-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-19</dc:identifier>
                                <prism:require>/content/figures/1471-2172-14-19-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2013-04-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/13">
        <title>Annual acknowledgement of manuscript reviewers</title>
        <description>Contributing reviewersThe editors of BMC Immunology would like to thank all of our reviewers who have contributed to the journal in Volume 13 (2012).</description>
        <link>http://www.biomedcentral.com/1471-2172/14/13</link>
                <dc:creator>Christopher Morrey</dc:creator>
                <dc:source>BMC Immunology 2013, null:13</dc:source>
        <dc:date>2013-04-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-13</dc:identifier>
                                <prism:require>/content/figures/1471-2172-14-13-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2013-04-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/18">
        <title>Expression profiling of lymph node cells from deer mice infected with Andes virus</title>
        <description>Background:
Deer mice (Peromyscus maniculatus) are the principal reservoir hosts of Sin Nombre virus (SNV), the cause of the great majority of hantavirus cardiopulmonary syndrome (HCPS) cases in North America. SNV, like all hantaviruses with their reservoirs, causes persistent infection without pathology in deer mice and appear to elicit a regulatory T cell response. Deer mice are also susceptible to Andes virus (ANDV), which causes the great majority of HCPS cases in South America, but they clear infection by 56&#160;days post infection without signs of disease.
Results:
We examined lymph node cell responses of deer mice infected with ANDV to determine expression profiles upon in vitro recall challenge with viral antigen. Because the deer mouse genome is currently unannotated, we developed a bioinformatics pipeline to use known lab mouse (Mus musculus) cDNAs to predict genes within the deer mouse genome and design primers for quantitative PCR (http://dna.publichealth.uga.edu/BlastPrimer/BlastPrimer.php). Of 94 genes examined, 20 were elevated, the plurality of which were Th2-specific, whereas 12 were downregulated. Other expressed genes represented Th1, regulatory T cells and follicular helper T cells, and B cells, but not Th17 cells, indicating that many cellular phenotypes participate in the host response to Andes virus.
Conclusions:
The ability to examine expression levels of nearly any gene from deer mice should allow direct comparison of infection with SNV or ANDV to determine the immunological pathways used for clearance of hantavirus infection in a reservoir host species.</description>
        <link>http://www.biomedcentral.com/1471-2172/14/18</link>
                <dc:creator>Tony Schountz</dc:creator>
                <dc:creator>Timothy Shaw</dc:creator>
                <dc:creator>Travis Glenn</dc:creator>
                <dc:creator>Heinz Feldmann</dc:creator>
                <dc:creator>Joseph Prescott</dc:creator>
                <dc:source>BMC Immunology 2013, null:18</dc:source>
        <dc:date>2013-04-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-18</dc:identifier>
                            <dc:title>Profiling immune responses of deer mice</dc:title>
                            <dc:description>&lt;p&gt;Novel methodology for designing real-time PCR arrays in deer mice indicates that lymph node T cells from those infected with ANDV express mostly genes of the Th2 phenotype but fewer genes of Th1 and Treg phenotypes.&lt;/p&gt;</dc:description>
                <prism:require>/content/figures/1471-2172-14-18-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2013-04-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/17">
        <title>Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock</title>
        <description>Background:
In sepsis, tumor necrosis factor (TNF) is the key factor triggering respiratory burst, tissue injury and disseminated coagulation. Anti-TNF strategies based on monoclonal antibodies or F(ab&#8217;)2 fragments have been used in sepsis with contradictory results. Immunoglobulin new antigen receptors (IgNAR) are a unique subset of antibodies consisting of five constant (CNAR) and one variable domains (VNAR). VNAR domains are the smallest, naturally occurring, antibody-based immune recognition units, having potential use as therapy.Our aim was to explore the impact of an anti-TNF VNAR on survival in an experimental model of endotoxic shock. Also, mRNA expression and serum protein of several inflammatory molecules were measured.
Results:
Endotoxic shock was induced by lipopolysaccharide (LPS) in male Balb/c mice. Animals were treated with anti-TNF VNAR domains, F(ab&#8217;)2 antibody fragments, or saline solution 15 minutes before, 2&#8201;h and 24&#8201;h after lethal dose100 (LD100) LPS administration. TNF blockade with either VNAR domains or F(ab&#8217;)2 fragments were associated with lower mortality (60% and 75%, respectively) compared to LD100. Challenge with LPS induced significant production of serum TNF and interleukins -10 and -6 at 3&#8201;h. After that, significant reduction of IL-6 at 24&#8201;h (vs 3&#8201;h) was shown only in the VNAR group. Nitrites level also increased in response to LPS.In liver, TNF and IL-10 mRNA expression showed a pro-inflammatory imbalance in response to LPS. Blocking TNF was associated with a shift towards an anti-inflammatory status; however, polarization was more pronounced in animals receiving F(ab&#8217;)2 fragments than in those with VNAR therapy. With regard to IL-6, gene expression was increased at 3&#8201;h in all groups. TNF blockade was associated with rapid and sustained suppression of IL-6 expression, even more evident in the VNAR group. Finally, expression of inducible-nitric oxide synthase (iNOS) increased in response to LPS at 3&#8201;h, but this was decreased at 24 h only in the anti-TNF VNAR group.
Conclusions:
Anti-TNF VNAR single domains improved survival in a murine model of endotoxic shock. Protection was associated with regulation in the TNF/IL-10 balance, attenuation of IL-6 and iNOS gene expression in the liver as well as decreased serum IL-6 concentration.</description>
        <link>http://www.biomedcentral.com/1471-2172/14/17</link>
                <dc:creator>Rafael Bojalil</dc:creator>
                <dc:creator>María Mata-González</dc:creator>
                <dc:creator>Fausto Sánchez-Muñoz</dc:creator>
                <dc:creator>Yepci Yee</dc:creator>
                <dc:creator>Iván Argueta</dc:creator>
                <dc:creator>Lucía Bolaños</dc:creator>
                <dc:creator>Luis Amezcua-Guerra</dc:creator>
                <dc:creator>Tanya Camacho-Villegas</dc:creator>
                <dc:creator>Edna Sánchez-Castrejón</dc:creator>
                <dc:creator>Walter García-Ubbelohde</dc:creator>
                <dc:creator>Alexei Licea-Navarro</dc:creator>
                <dc:creator>Ricardo Márquez-Velasco</dc:creator>
                <dc:creator>Jorge Paniagua-Solís</dc:creator>
                <dc:source>BMC Immunology 2013, null:17</dc:source>
        <dc:date>2013-04-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-17</dc:identifier>
                                <prism:require>/content/figures/1471-2172-14-17-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2013-04-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/16">
        <title>BATF regulates the development and function of IL-17 producing iNKT cells</title>
        <description>Background:
BATF plays important roles in the function of the immune system. Batf null mice are deficient in both CD4+ Th17 cells and T follicular helper cells and possess an intrinsic B cell defect that leads to the complete absence of class switched Ig. In this study, Tg mice overexpressing BATF in T cells were used together with Batf null mice to investigate how altering levels of BATF expression in T cells impacts the development and function of a recently characterized population of iNKT cells expressing IL-17 (iNKT-17).
Results:
BATF has a direct impact on IL-17 expression by iNKT cells. However, in contrast to the Th17 lineage where BATF activates IL-17 expression and leads to the expansion of the lineage, BATF overexpression restricts overall iNKT cell numbers while skewing the compartment in vivo and in vitro toward an iNKT-17 phenotype.
Conclusions:
This work is the first to demonstrate that BATF joins ROR&#947;t as the molecular signature for all IL-17 producing cells in vivo and identifies BATF as a component of the nuclear protein network that could be targeted to regulate IL-17-mediated disease. Interestingly, these studies also reveal that while the Il17a gene is a common target for BATF regulation in Th17 and iNKT-17 cells, this regulation is accompanied by opposite effects on the growth and expansion of these two cell lineages.</description>
        <link>http://www.biomedcentral.com/1471-2172/14/16</link>
                <dc:creator>Kimberly Jordan-Williams</dc:creator>
                <dc:creator>Stacie Poston</dc:creator>
                <dc:creator>Elizabeth Taparowsky</dc:creator>
                <dc:source>BMC Immunology 2013, null:16</dc:source>
        <dc:date>2013-03-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-16</dc:identifier>
                                <prism:require>/content/figures/1471-2172-14-16-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2013-03-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/14/15">
        <title>Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels</title>
        <description>In holoendemic Plasmodium falciparum transmission areas such as western Kenya, severe malarial anemia [SMA, hemoglobin (Hb)&#8201;&lt;&#8201;6.0&#8201;g/dL, with any density parasitemia] is the most common clinical manifestation of severe malaria resulting in high rates of pediatric morbidity and mortality in these regions. Previous studies associated interleukin (IL)-13 with pathogenesis of different infectious diseases, including P. falciparum malaria. However, the functional roles of polymorphic variants within the IL-13 promoter in conditioning susceptibility to SMA remain largely unexplored. As such, the association between the IL-13 variants -7402&#8201;T/G (rs7719175) and -4729G/A (rs3091307) and susceptibility to SMA was determined in children (n&#8201;=&#8201;387) presenting with clinical symptoms of falciparum malaria and resident in a holoendemic transmission region in western Kenya. Our results indicated no difference in the proportions of individual genotypes among children presenting with non-SMA (n&#8201;=&#8201;222) versus SMA (n&#8201;=&#8201;165). Similarly, there was no associations between the individual genotypes (-7402&#8201;T/G and -4729G/A) and SMA. Additional analyses, however, revealed that proportions of individuals with -7402&#8201;T/-4729A (TA) haplotype was significantly higher in children presenting with SMA than non-SMA group (P&#8201;=&#8201;0.043). A further multivariate logistic regression analyses, controlling for confounding factors, demonstrated that carriage of the TA haplotype was associated with increased susceptibility to SMA (OR; 1.564, 95% CI; 1.023-2.389, P&#8201;=&#8201;0.039). In addition, circulating levels of IL-13 were comparable between the clinical groups as well as across genotypes and haplotypes. Collectively, findings presented here suggest that haplotypes within the IL-13 promoter at -7402&#8201;T/G and -4729G/A may modulate SMA pathogenesis, but do not affect circulating IL-13 levels.</description>
        <link>http://www.biomedcentral.com/1471-2172/14/15</link>
                <dc:creator>Winnie Okeyo</dc:creator>
                <dc:creator>Elly Munde</dc:creator>
                <dc:creator>Wilson Okumu</dc:creator>
                <dc:creator>Evans Raballah</dc:creator>
                <dc:creator>Samuel Anyona</dc:creator>
                <dc:creator>John Vulule</dc:creator>
                <dc:creator>John Ong¿echa</dc:creator>
                <dc:creator>Douglas Perkins</dc:creator>
                <dc:creator>Collins Ouma</dc:creator>
                <dc:source>BMC Immunology 2013, null:15</dc:source>
        <dc:date>2013-03-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-14-15</dc:identifier>
                                <prism:require>/content/figures/1471-2172-14-15-toc.gif</prism:require>
                <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2013-03-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
